Sunitinib (Sutent)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including: vascular endothelial growth factor receptor (VEGFR1, VEGFR2 and VEGFR3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and RET. Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  1. "for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate."
  2. "for the treatment of advanced renal cell carcinoma."

Also known as

  • Code names: SU11248, SU011248
  • Brand names: Suninat, Sutent


  1. 1.0 1.1 1.2 Sunitinib (Sutent) package insert
  2. Sunitinib (Sutent) package insert (locally hosted backup)
  3. Sutent manufacturer's website
  4. Sunitinib (Sutent) patient drug information (Chemocare)
  5. Sunitinib (Sutent) patient drug information (UpToDate)